T. Rowe Price Associates
RGEN icon

T. Rowe Price Associates’s Repligen RGEN Stock Holding History

T. Rowe Price Associates’s Portfolio RGEN Stock Details RGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$575M Buy
4,878,141
+279,080
+6% +$39M 0.07% 230
2025
Q4 		$754M Buy
4,599,061
+1,091,683
+31% +$171M 0.08% 186
2025
Q3 		$469M Sell
3,507,378
-3,096,576
-47% -$376M 0.05% 281
2025
Q2 		$821M Sell
6,603,954
-962,139
-13% -$122M 0.09% 188
2025
Q1 		$963M Buy
7,566,093
+430,039
+6% +$66.2M 0.12% 174
2024
Q4 		$1.03B Buy
7,136,054
+743,815
+12% +$107M 0.12% 159
2024
Q3 		$951M Buy
6,392,239
+1,783,806
+39% +$256M 0.11% 175
2024
Q2 		$581M Buy
4,608,433
+1,040,117
+29% +$163M 0.07% 246
2024
Q1 		$656M Sell
3,568,316
-441,939
-11% -$84.2M 0.08% 229
2023
Q4 		$721M Buy
4,010,255
+208,413
+5% +$32.4M 0.1% 198
2023
Q3 		$605M Buy
3,801,842
+85,077
+2% +$13.9M 0.09% 217
2023
Q2 		$526M Sell
3,716,765
-45,033
-1% -$7.22M 0.07% 242
2023
Q1 		$633M Sell
3,761,798
-1,308,859
-26% -$234M 0.09% 215
2022
Q4 		$859M Buy
5,070,657
+1,411,078
+39% +$256M 0.14% 152
2022
Q3 		$685M Sell
3,659,579
-1,871,942
-34% -$395M 0.11% 173
2022
Q2 		$898M Buy
5,531,521
+1,755,417
+46% +$278M 0.11% 196
2022
Q1 		$710M Buy
3,776,104
+733,449
+24% +$139M 0.07% 267
2021
Q4 		$806M Buy
3,042,655
+737,206
+32% +$199M 0.07% 263
2021
Q3 		$666M Buy
2,305,449
+550,303
+31% +$141M 0.06% 299
2021
Q2 		$350M Buy
1,755,146
+435,972
+33% +$84.6M 0.03% 423
2021
Q1 		$256M Buy
1,319,174
+130,709
+11% +$26.8M 0.03% 482
2020
Q4 		$228M Buy
1,188,465
+214,585
+22% +$39M 0.02% 491
2020
Q3 		$144M Sell
973,880
-802,550
-45% -$115M 0.02% 562
2020
Q2 		$220M Sell
1,776,430
-272,503
-13% -$32.1M 0.03% 453
2020
Q1 		$198M Buy
2,048,933
+1,401,743
+217% +$135M 0.03% 416
2019
Q4 		$59.9M Buy
647,190
+4,721
+0.7% +$397K 0.01% 850
2019
Q3 		$49.3M Buy
642,469
+30,684
+5% +$2.68M 0.01% 879
2019
Q2 		$52.6M Buy
611,785
+22,063
+4% +$1.5M 0.01% 871
2019
Q1 		$34.8M Buy
589,722
+7,708
+1% +$443K 0.01% 999
2018
Q4 		$30.7M Buy
582,014
+39,591
+7% +$2.32M 0.01% 993
2018
Q3 		$30.1M Buy
542,423
+79,058
+17% +$4.07M ﹤0.01% 1091
2018
Q2 		$21.8M Buy
463,365
+11,812
+3% +$486K ﹤0.01% 1177
2018
Q1 		$16.3M Buy
451,553
+12,668
+3% +$445K ﹤0.01% 1249
2017
Q4 		$15.9M Buy
438,885
+2,267
+0.5% +$82.1K ﹤0.01% 1256
2017
Q3 		$16.7M Buy
436,618
+46,830
+12% +$1.96M ﹤0.01% 1230
2017
Q2 		$16.2M Buy
389,788
+63,724
+20% +$2.42M ﹤0.01% 1230
2017
Q1 		$11.5M Buy
326,064
+75,174
+30% +$2.38M ﹤0.01% 1306
2016
Q4 		$7.73M Buy
250,890
+1,800
+0.7% +$55.7K ﹤0.01% 1359
2016
Q3 		$7.52M Buy
249,090
+44,700
+22% +$1.35M ﹤0.01% 1363
2016
Q2 		$5.59M Buy
204,390
+12,400
+6% +$317K ﹤0.01% 1388
2016
Q1 		$5.15M Buy
191,990
+2,000
+1% +$48.9K ﹤0.01% 1395
2015
Q4 		$5.38M Buy
189,990
+33,190
+21% +$957K ﹤0.01% 1403
2015
Q3 		$4.37M Buy
156,800
+41,800
+36% +$1.51M ﹤0.01% 1453
2015
Q2 		$4.75M Buy
+115,000
New +$4.21M ﹤0.01% 1491

Other funds holding RGEN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates's RGEN Position: Q1 2026 in Review

T. Rowe Price Associates increased its Repligen (RGEN) stake by 6.1% in Q1 2026, buying an estimated $39M and bringing the position to 4,878,141 shares worth $575M. The position accounts for 0.07% of the portfolio, ranked #230.

T. Rowe Price Associates first reported a position in RGEN in Q2 2015 and has held it in 44 quarters since. The position peaked at $1.03B in Q4 2024. 441 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

  • T. Rowe Price Associates held 4,878,141 shares of Repligen worth $575M as of Q1 2026.
  • T. Rowe Price Associates bought 279,080 Repligen shares in Q1 2026, an estimated $39M.
  • Repligen made up 0.07% of T. Rowe Price Associates's portfolio in Q1 2026, its #230 holding.
  • T. Rowe Price Associates first reported a position in Repligen in Q2 2015 and has held it in 44 quarters since.
  • T. Rowe Price Associates's Repligen position peaked at $1.03B in Q4 2024.
  • 441 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.